Tethys BioScience Inc

Emeryville, CA, United States

Tethys BioScience Inc

Emeryville, CA, United States
SEARCH FILTERS
Time filter
Source Type

Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 L or less of a legacy clinical sample.


Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 L or less of a legacy clinical sample.


Patent
Tethys Bioscience Inc. | Date: 2013-03-14

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.


Patent
Tethys Bioscience Inc. | Date: 2013-01-02

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.


Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 L or less of a legacy clinical sample.


Patent
Tethys Bioscience Inc. | Date: 2011-03-30

Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluatinig the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.


Patent
Tethys Bioscience Inc. | Date: 2011-10-05

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.


Patent
Tethys Bioscience Inc. | Date: 2010-10-28

A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.


Patent
Tethys Bioscience Inc. | Date: 2013-03-11

Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.


Patent
Tethys Bioscience Inc. | Date: 2010-04-21

Disclosed are methods of identifying subjects with Diabetes or a pre-diabetic condition, methods of identifying subjects at risk for developing Diabetes or a pre-diabetic condition, methods of differentially diagnosing diseases associated with Diabetes or a pre- diabetic condition from other diseases or within sub-classifications of Diabetes, methods of evaluating the risk of progression to Diabetes or a pre-diabetic condition in patients, methods of evaluating the effectiveness of treatments in subjects with Diabetes or a pre-diabetic condition, and methods of selecting therapies for treating Diabetes or a pre-diabetic condition, using biomarkers.

Loading Tethys BioScience Inc collaborators
Loading Tethys BioScience Inc collaborators